Biodexa Pharmaceuticals Files SEC Report

TL;DR

Biodexa (BDXA) filed a 6-K with the SEC on May 22, 2024. Standard compliance update.

AI Summary

Biodexa Pharmaceuticals PLC announced on May 22, 2024, that it has filed a report with the SEC. The company, formerly known as Midatech Pharma Plc, is based in Cardiff, United Kingdom, and operates in the Pharmaceutical Preparations industry. This filing is a routine report under the 1934 Securities Exchange Act.

Why It Matters

This filing indicates ongoing regulatory compliance and provides an update on the company's official disclosures to the market.

Risk Assessment

Risk Level: low — This filing is a routine report and does not contain new material financial or operational information that would inherently increase risk.

Key Numbers

• 001-37652 — SEC File Number (Identifies the company's filing history with the SEC)

Key Players & Entities

• Biodexa Pharmaceuticals PLC (company) — Filer of the report
• Midatech Pharma Plc (company) — Former name of the company
• May 22, 2024 (date) — Date of filing
• Cardiff, United Kingdom (location) — Company's principal executive offices

FAQ

Key Financial Figures

• $2.50 — 6,054,230 ADSs at an exercise price of $2.50 per share. In connection with the exe
• $6.05 m — eceived gross proceeds of approximately $6.05 million, before deducting placement agent

Filing Documents

• g5282416k.htm (6-K) — 15KB
• ex4_1.htm (EX-4.1) — 122KB
• ex4_2.htm (EX-4.2) — 122KB
• ex4_3.htm (EX-4.3) — 122KB
• 0001214659-24-010057.txt ( ) — 381KB

From the Filing

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ FORM 6-K ___________________________ REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant’s name into English) 1 Caspian Point, Caspian Way Cardiff, CF10 4DQ, United Kingdom (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨ EXPLANATORY NOTE On May 22, 2024, Biodexa Pharmaceuticals PLC (the “Company”) filed a report on Form 6-K announcing that the Company had entered into letter agreements (the “Agreements”) with certain accredited investors (collectively, the “Holders”) of the Company’s outstanding Series E warrants (“Series E Warrants”) and Series F warrants (“Series F Warrants”) issued on December 21, 2023 (collectively, the “Existing Warrants”). This report on Form 6-K is being filed to report the closing of the previously disclosed transaction and to correct certain scrivener errors contained in the previously filed report on Form 6-K, as well as in Exhibits 4.1 and 4.2, which are re-filed hereto, and to update the gross proceeds from warrant exercises previously announced by the Company. Warrant Inducement Transaction On May 24, 2024, the Company closed the transactions contemplated by the Agreements (the “Closing”). Pursuant to the terms of the Agreements, each Holder who exercised its Existing Warrants received one (1) replacement warrant for each Series E Warrant exercised (the “Series G Warrants”) and one (1) replacement warrant for each Series F Warrant exercised (“Series H Warrants,” and collectively with the Series G Warrants, the “Replacement Warrants”). The Holders collectively exercised an aggregate of 4,036,151 Existing Warrants consisting of: (i) 1,572,674 Series E Warrants and (ii) 2,463,477 Series F Warrants. As a result of the exercises, the Company will, subject to certain Existing Warrants being held in abeyance, issue an aggregate of 4,036,151 of its American depositary shares (“ADSs”), with each ADS representing 400 of the Company’s ordinary shares, nominal value £0.001 per share. In connection therewith, the Company issued Replacement Warrants to the Holders exercisable for an aggregate of 6,054,230 ADSs at an exercise price of $2.50 per share. In connection with the exercise of the Existing Warrants, the Company received gross proceeds of approximately $6.05 million, before deducting placement agent fees and estimated offering expenses. On May 24, 2024, in connection with the Closing, the Company issued placement agent warrants to purchase an aggregate of 161,446 ADSs to Ladenburg Thalmann & Co., Inc. The information included in this report on Form 6-K, including Exhibits 4.1, 4.2 and 4.3, shall be deemed to be incorporated by reference into the registration statements on Form S-8 (File No. 333-214969) and Form F-3 (File No. 333-233901) of the Company (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. 2 SUBMITTED HEREWITH Attached to the Registrant’s Form 6-K filing for the month of May 2024 is: Exhibit No. Description 4.1 Form of Series G Warrant. 4.2 Form of Series H Warrant. 4.3 Form of Placement Agent Warrant. 3 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Biodexa Pharmaceuticals PLC Date: May 28, 2024 By: /s/ Stephen Stamp Stephen Stamp Chief Executive Officer and Chief Financial Officer 4

View Full Filing

View this 6-K filing on SEC EDGAR